Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's consumer health unit, Bloomberg News reported on Thursday.

Sanofi and partner Regeneron on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster...

French drugmaker Sanofi is nearing a decision to invest between 1.3 billion and 1.5 billion euros ($1.4-$1.6 billion) to upgrade its production of long-acting insulin shots in Germany, a person fam...

French drugmaker Sanofi is nearing a decision to invest between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) at a major production site in Frankfurt, Germany, where it makes insulin ...

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negotiation for license of Company's small molecule TREM2...

ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusiran Seven oral presentations across the hemophilia portfolio reinforce Sanofi's commitment to bring potential fi...

Belharra today announced a strategic collaboration with Sanofi to advance the discovery of novel small molecule therapeutics for immunological diseases.

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that updated efficacy and safety resul...

Sanofi's shares have not fully recovered since announcing a business strategy change in October 2023, focusing on R&D investments and on separating its consumer healthcare business unit. The compan...

In recent weeks, Sanofi has pleased investors with progress in the development of its pipeline of experimental drugs. On May 20, 2024, SNY announced additional results from a Phase 3 clinical trial...

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

Sanofi launches 2024 global Employee Stock Purchase Plan Paris, May 31, 2024. Sanofi's global employee shareholder plan, Action 2024, opens on June 4, 2024, to around 80,000 employees in 56 countries.

French drugmaker Sanofi and its partner Regeneron said on Friday the U.S. Food and Drug Administration (FDA) requested additional analyses on the efficacy of Dupixent as an add-on treatment in cert...

The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.

A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix,...